Last reviewed · How we verify
Pentoxifylline plus Metadoxine
Pentoxifylline improves blood flow and reduces blood viscosity while metadoxine enhances cellular metabolism and liver function, together addressing microcirculatory dysfunction and metabolic support.
Pentoxifylline improves blood flow and reduces blood viscosity while metadoxine enhances cellular metabolism and liver function, together addressing microcirculatory dysfunction and metabolic support. Used for Alcoholic liver disease, Hepatic cirrhosis with microcirculatory dysfunction.
At a glance
| Generic name | Pentoxifylline plus Metadoxine |
|---|---|
| Sponsor | Hospital General de Mexico |
| Drug class | Rheological agent plus metabolic support agent |
| Modality | Small molecule |
| Therapeutic area | Hepatology; Vascular/Microcirculation |
| Phase | FDA-approved |
Mechanism of action
Pentoxifylline is a methylxanthine derivative that decreases blood viscosity, improves erythrocyte deformability, and enhances tissue oxygenation by reducing platelet aggregation and increasing blood flow. Metadoxine (pyridoxine pyroglutamate) acts as a cofactor in cellular metabolism and supports hepatic detoxification pathways. The combination targets both microcirculatory impairment and metabolic dysfunction.
Approved indications
- Alcoholic liver disease
- Hepatic cirrhosis with microcirculatory dysfunction
Common side effects
- Gastrointestinal disturbance
- Dizziness
- Headache
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentoxifylline plus Metadoxine CI brief — competitive landscape report
- Pentoxifylline plus Metadoxine updates RSS · CI watch RSS
- Hospital General de Mexico portfolio CI